AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen (rintatolimod) in Combination with AstraZeneca's Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer
14.02.2024 - Phase 1b portion of the study expected to be completed within six monthsOCALA, Fla., Feb. 14, 2024 (GLOBE NEWSWIRE) - AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the first subject has been dosed at Erasmus ...
Source: wallstreet-online.de
